Children with the common inherited disorder neurofibromatosis, type 1 (NF1) are predisposed to myeloid leukemia, particularly juvenile chronic myelomonocytic leukemia (JMML). The NF1 gene (NF1) encodes a GTPase activating protein (GAP) called neurofibromin that stimulates GTP hydrolysis on the p21ras (Ras) family of signaling proteins. We have shown that NF1 functions as a tumor suppressor gene in myeloid cells by negatively regulating Ras. In the current period of support, we have exploited a murine model to investigate mechanistic questions related to the role of NF1 in myeloid growth control and to perform preclinical studies of rational therapeutics. These studies strongly implicate the growth factor GM-CSF as playing a central role in the aberrant growth of murine NF1 mutant cells and in human JMML. In the competing renewal of this translational research project, we will extend these studies using expertise and reagents developed during the past 4 years. This application has 4 specific aims. The experiments proposed under aim 1 involve detailed mechanistic studies of the effects of NF1 inactivation on signal transduction, apoptosis, and cell cycle control in myeloid lineage cells. We will also take a genetic approach to test the role of GM-C SF signaling in a myeloproliferative disorder (MPD) that arises in JunB mutant mice.
In aim 2, we propose studies to elucidate the role of GM-CSF in fetal liver cell engraftment that might be relevant to the pathogenesis of JMML.
Our third aim proposes a combination of in vivo and in vitro approaches to contrast the effects of expressing oncogenic Ras and inactivating NF1 in myeloid cells. These studies will exploit a novel mouse model developed by our collaborator Tyler Jacks.
In aim 4, we examine how the adapter molecule p62DOK regulates myeloid growth by interacting with the Ras GTPase activating protein p12OGAP. Together, these studies will provide new insights into how Ras signaling is normally regulated in myeloid cells, and how hyperactive Ras contributes to leukemogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072614-07
Application #
6621864
Study Section
Special Emphasis Panel (ZRG1-PTHC (01))
Program Officer
Mufson, R Allan
Project Start
1997-02-15
Project End
2007-01-31
Budget Start
2003-02-01
Budget End
2004-01-31
Support Year
7
Fiscal Year
2003
Total Cost
$302,544
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Burgess, Michael R; Hwang, Eugene; Mroue, Rana et al. (2017) KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell 168:817-829.e15
North, Matthew; Shuga, Joe; Fromowitz, Michele et al. (2014) Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer 14:6
Diaz-Flores, Ernesto; Goldschmidt, Hana; Depeille, Philippe et al. (2013) PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 6:ra105
Shannon, Kevin; Armstrong, Scott A (2010) Genetics, epigenetics, and leukemia. N Engl J Med 363:2460-1
Loh, Mignon L; Sakai, Debbie S; Flotho, Christian et al. (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 114:1859-63
Denayer, Ellen; Parret, Annabel; Chmara, Magdalena et al. (2008) Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29:232-9
Haigis, Kevin M; Kendall, Krystle R; Wang, Yufang et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600-8
Van Meter, Margaret E M; Diaz-Flores, Ernesto; Archard, Joehleen A et al. (2007) K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109:3945-52
Sovik, Oddmund; Schubbert, Suzanne; Houge, Gunnar et al. (2007) De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 44:e84
Diaz-Flores, Ernesto; Shannon, Kevin (2007) Targeting oncogenic Ras. Genes Dev 21:1989-92

Showing the most recent 10 out of 43 publications